Today: 9 June 2026
Boeing stock dips after hours as Pentagon awards $2.7 billion Apache support contract
31 December 2025
2 mins read

Boeing stock dips after hours as Pentagon awards $2.7 billion Apache support contract

NEW YORK, December 31, 2025, 5:20 PM ET — After-hours

  • Boeing shares fell about 0.6% in after-hours trading, tracking a weaker finish for U.S. stocks.
  • A Pentagon contract notice showed Boeing won a $2.73 billion Army award for Apache helicopter post-production support.
  • Investors are watching whether defense work can underpin cash flow as Boeing navigates tight FAA oversight of its commercial jet output.

Boeing shares slipped in after-hours trading on Wednesday after a Pentagon contracts notice showed the company won an Army award worth about $2.7 billion tied to Apache helicopter support. Boeing stock was down about 0.6% at $217.12.

The latest award matters because Boeing is leaning on steadier defense work to balance a still-scrutinized commercial jet business. With markets heading into a holiday break, investors have been quick to latch onto any sign of durable revenue and cash generation going into 2026.

A Reuters Breakingviews column noted that roughly a third of Boeing’s revenue comes from its defense, space and security segment, which depends on government contracts. It also pointed to Wall Street price targets implying a 38% rise over the next 12 months, based on Visible Alpha data as of late November.

The Army notice listed the Boeing award at $2,728,234,918 and described it as a firm-fixed-price contract — meaning the price is set and Boeing typically bears more of the cost overrun risk. The work locations and funding will be set with each order under the contract, with an estimated completion date of Dec. 31, 2030.

The Apache support award landed two days after the Pentagon announced an $8.6 billion Boeing contract for the F-15 Israel Program, including 25 new F-15IA jets with an option for 25 more. The Pentagon said contract work would be performed in St. Louis and was expected to be completed by Dec. 31, 2035.

Boeing stock traded between $216.14 and $219.50 during the regular session, LSEG data showed. It closed the year-end session as U.S. indexes fell, with the Dow down 0.63% and the S&P 500 down 0.74%.

Thin holiday volumes helped amplify moves across the tape. “It’s perfectly fine in any bull market to have moments of cost,” said Giuseppe Sette, co-founder and president of Reflexivity. Reuters

Boeing’s defense wins also keep the company in the center of Washington’s industrial policy debate. The Breakingviews column argued a U.S. government investment in Boeing would fit a broader push toward “state capitalism,” given Boeing’s role as a major military supplier and exporter. Reuters

At the same time, the commercial side remains a key swing factor for equity investors. Breakingviews said the Federal Aviation Administration limits how many 737 MAX planes Boeing can make and can shape how much autonomy the company has in conducting inspections — oversight that investors see as a gatekeeper for any production rebound.

Competitive pressures remain in the background. Boeing and Airbus dominate large commercial jetmaking — a duopoly, meaning a market led by two players — while Breakingviews highlighted state-backed rivals, noting that the German, French and Spanish governments collectively own about a quarter of Airbus.

Traders now look to the next full session for follow-through, after U.S. stock markets close Thursday for New Year’s Day and reopen Friday. Any fresh Pentagon awards, FAA signals, or company updates on inspections and production will likely be the next headline catalysts for Boeing shares.

For now, Boeing ended the year just below the $220 level it tested during the session, leaving investors to weigh whether the latest defense contract flow can offset lingering uncertainty around commercial output in early 2026.

Stock Market Today

  • Redwire Shares Fall After $500 Million At-The-Market Stock Offering Announcement
    June 9, 2026, 10:33 AM EDT. Redwire Corp shares dropped 6.5% after the company filed a $500 million at-the-market (ATM) stock program with the U.S. SEC. The ATM program allows Redwire to sell shares gradually at prevailing prices, providing flexible capital raising but risking shareholder dilution. The stock slide comes despite strong underlying demand, with CEO Peter Cannito citing a $498 million backlog and a 57.9% revenue jump in Q1. Redwire's $3.37 billion market cap contrasts with its ongoing net losses, and CEO reaffirmed 2026 revenue guidance of $450-$500 million. The stock decline was specific to Redwire following its financing news, while other space sector peers advanced.

Latest articles

Autozi Shares Jump 400%, Filing Flags Risks for AZI

Autozi Shares Jump 400%, Filing Flags Risks for AZI

9 June 2026
Autozi Internet Technology shares soared over 400% to $5.69 in early Nasdaq trading after a 10-for-1 share consolidation slashed its share count to about 4.49 million, but the surge contrasts with a 63.1% revenue drop, 82.5% plunge in gross profit, and widened net loss, with the company warning of “substantial doubt” about its ability to continue as a going concern.
Redwire Shares Slip After $500 Million Stock Offering Filed

Redwire Shares Slip After $500 Million Stock Offering Filed

9 June 2026
Redwire Corp shares plunged 6.5% to $17.37 after launching a $500 million at-the-market stock program, raising dilution risks for investors as the company seeks flexible funding despite recent record backlog and strong revenue growth; the drop contrasted with gains at other space stocks, highlighting investor concern over potential share issuance.
Nuvalent Trades Close to $124 After GSK’s $10.6 Billion Offer

Nuvalent Trades Close to $124 After GSK’s $10.6 Billion Offer

9 June 2026
Nuvalent shares soared 38.9% to $122.93, just below GSK’s $124-a-share cash offer after the $10.6 billion buyout was announced, as investors bet on the deal closing with Nuvalent’s two lead lung-cancer drugs already under FDA review and a 40% premium to the last closing price driving the morning’s merger-arb trade.
Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
Why FICO Stock Is Sliding Today: Fair Isaac Drops in Thin Year-End Trading
Previous Story

Why FICO Stock Is Sliding Today: Fair Isaac Drops in Thin Year-End Trading

Outlook Therapeutics stock drops after FDA issues another Lytenava CRL for wet AMD
Next Story

Outlook Therapeutics stock drops after FDA issues another Lytenava CRL for wet AMD

Go toTop